Blood Biomarkers Dynamic Detection, Especially Eosinophils has Certain Value in the Clinical Diagnosis, Severity Classification and Prognosis Judgment of COVID-19

Abstract

In December 2019, coronavirus disease 2019 (COVID-19) was first found in Wuhan, China and soon was reported all around the world. Novel coronavirus (COVID-19) is highly infectious and requires early detection, isolation, and treatment. We tried to find some useful information by analyzing the covid-19 screening data, so as to provide help for clinical practice. In this prospective study, we retrospectively analyzed the clinical data of 131 patients with COVID-19 and 119 controls. For confirmed cases, the data of blood routine examination were analyzed among severe patients and non-severe group. The blood routine examination results were dynamically observed in the survivors and nonsurvivors. We find that patients with COVID-19 have lower counts of leucocytes, lymphocytes, eosinophils, which were compared with controls (P < 0.001). In severe group, patients have the lower count of lymphocytes and eosinophils, but the higher leucocytes count (all P values < 0.01). Eosinophils have high diagnostic efficacy analysis of severe COVID-19, and its area under the curve reached 0.750. Patients whose eosinophils returned to normal early had significantly longer survival times than those who did not(P < 0.001). Patients with COVID-19 have abnormal peripheral blood routine examination results. Dynamic surveillance of peripheral blood system especially eosinophils is helpful in the diagnosis, assess the prognosis and prediction of severe COVID-19 cases.